Fig. 5

CANA inhibits rPASMCs proliferation and migration. a CCK-8 assay in rPASMCs treated with CANA (0, 0.5, 1, 2, 5, 10, and 20 μM) under normoxia condition (n = 6 independent experiments). b CCK-8 assay in rPASMCs treated with CANA (0, 2, 5, 10, and 20 μM), compared with hypoxia group (n = 6 independent experiments). c Immunostaining of Ki67 (green) in rPASMCs under different CANA concentrations (0, 2, 5,10, and 20 μM) (scale bars = 20 μm). d Cell migration was detected by wound-healing assays at 0, 12, and 24 h (scale bars = 100 μm). e Quantification of Ki67⁺/DAPI⁺ cells in each group (n = 6 sections from six independent experiments, three images per section). f Quantification of wound closure (n = 6 independent experiments). ^nsP > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.